Spana (2005) Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response Urology, Volume 65, Issue 4, April 2005, Pages 755-759
The synergistic stimulation results in increased IGF-1 levels and prolonged anabolic signaling, promoting protein synthesis, lean muscle development, and recovery in research models
all require qualified healthcare provider supervision and regular monitoring
Lilly CEO David Ricks framed the approval in terms of access: " Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment, " Ricks said in the company's April 1 press release